Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke

Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke: Effect of Intravenous Fibrinolysis With Rt-PA

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02860260

Acronym

BDNF

Enrollment

Registered

2016-08-09

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

BDNF

Brief summary

The aim of this study is to show for the first time that treatment with intravenous fibrinolysis using rt-PA in patients with recent ischemic stroke is accompanied by increases in circulating levels of BDNF, which may reflect an increase in BDNF synthesis in the brain. The analysis of the recovery of functional and cognitive abilities as well as mood at 3 months will allow us to study the impact of BDNF on these parameters. Thus, depending on the results obtained, circulating BDNF could serve as an early marker of these.

Interventions

BIOLOGICALBlood samples

OTHERCerebral MRI

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients (or their person of trust in cases of inability) who have been informed about the research and given their consent to take part * Patients aged 18 years or older * Patients who have suffered a de novo recent ischemic stroke \< 12 hours * Patients who had cerebral imaging (CT-Scan or MRI) * Ischemic stroke severity, measured by the National Institute of Health Stroke Score (NIHSS), between 4 and 20

Exclusion criteria

Patients without national health insurance cover * Patients with a clinical history of stroke * Patients with cerebral or sub-arachnoid haemorrhage * Patients with a transient ischemic attack * Time of symptom onset unknown * Patients with severe aphasia at the time of the ischemic stroke defined by a sub-score for item 9 (best language) of the NIHSS ≥ 2 * Patients with dementia prior to the ischemic stroke * Patients with a significant loss of autonomy prior to the ischemic stroke, defined by a Rankin score ≥ 4 * Patients with aphasia before the ischemic stroke * Patients with a contra-indication for cerebral MRI * Pregnant or breast-feeding women * Adults under guardianship * Subjects in custody * Patients who do not speak French

Design outcomes

Primary

Measure	Time frame
Measurement of serum levels of BDNF	Change from baseline at Day1, Day 7 and Month 3
Measurement of plasma levels of BDNF	Change from baseline at Day1, Day 7 and Month 3

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026